According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle ...

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused ...

Cachexia is a condition in which patients affected by cancer or other chronic diseases become sick and lose weight.

According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle ...

DelveInsight's 'Cancer Cachexia Pipeline Insight 2025' report provides comprehensive global coverage of pipeline cancer cachexia therapies in various stages of clinical development, major ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Researchers have discovered a new potential drug target for the lethal wasting disease known as cancer cachexia. Their findings illustrate that even small groups of neurons in the brain can have an ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Cancer dominates the drug development pipeline, but industry has paid little attention over the years to cancer cachexia — the complex weight-loss syndrome that accounts for 20–30% of cancer deaths.

According to the National Cancer Institute, nearly one-third of cancer deaths can be attributed to a wasting syndrome known as cachexia. Cachexia, an indicator of the advanced stages of disease, is a ...